The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $478.12, a high ...

Zimislecel, Vertex’s investigational fully differentiated islet cell therapy with standard immunosuppression, is in the Phase 3 portion of the Phase 1/2/3 study in patients with T1D with severe ...

Vertex Pharmaceuticals (VRTX) announced several updates on the company’s type 1 diabetes portfolio. Vertex has completed enrollment and dosing in Parts A and B of the Phase 1/2 VX-264 study and ...

Vertex's cloud growth momentum remains strong, with a 27% y/y increase in 4Q24. Read more to see why I upgrade VERX stock ...

The PGIM Jennison Focused Growth Fund rose 5.7%, slightly underperforming the Russell 1000 Growth Index. Click here to read ...

Available for testing through AI Studio and the Gemini app, Gemini 2.5 Pro sets a new benchmark for AI performance and versatility ... and will be coming to Vertex AI soon. But let’s be real ...

Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...

Taylor Tepper covered banking, investing and pretty much everything else in personal finance for more than a decade, with his work appearing in the New York Times, Fortune and MONEY magazine, as ...

WHSmith has agreed to sell UK high street shops and is set for rebrand (Picture: Getty Images) One of the UK’s most recognisable high street names, WH Smith, is set to disappear from the high ...

Read about some of the St. Louis area's top high school girls track and field athletes as the season gets under way. Catch up on some highlights from an action-packed pair of games in Clayton.